Your Holy Grail To Biotech Profits!
Dear Esteemed Investors,
Let me ask you this question:?Instead of chasing, what if you can buy a stock before it flies?
If you don't know me, I'm Dr. Harvey Tran, Founder/CEO of the private biotech investment group,?Integrated BioSci Investing:?The #1 Biotech Service for Growth Investing and Power Catalysts Trading
As a physician-scientist, I eat, breathe, and live biotech, which gives me?an EDGE?in biotech investing/trading. And, I'm super excited in bringing that advantage to assist and serve you.
In this blog, I'll show you how you can position both your Long-Term Growth Biotch Investing while boosting its gain with periodic Power Catalyst Trades.
With significant initial starting capital, you can get your Rolls Royce Dawn this year! That way, you can ride in style as you capture your winds of fortune.
As a long-term M7 stock, ImmunoGen's lead medicine already gained accelerated approval to treat the deadly ovarian cancers.
For full approval, the company needs to clear the Phase 3 (MIRASOL) confirmatory trial.
Given that MIRASOL determines the fate of ImmunoGen, a positive data report can send the stock to the moon.?
Conversely, a negative event would cause the stock to crash.
In our?exclusive research?for members, I forecasted MIRASOL to be cleared with flying colors.?
Moreover, I alerted members to boost their profits by trading this event in our?5th Open-Mic Webinar.
As the FIRST and ONLY of its kind for biotech Private Investing Group, we'd go on Zoom where I present the investment thesis and take member's questions LIVE.
That way, I can better assist and serve our members.
As you can see, ImmunoGen published MIRASOL's extremely robust data on May 3rd.
Like a rocket ship on launch, ImmunoGen shares popped over 100% in a single trading session.?
In the previous portfolio blog, I?recommended?that you hold a long-term portfolio for Growth Biotech Investing.?
At the same time, you should also hold a separate portfolio for Power Catalyst Trading.
And, make sure you follow?three winning habits?like boosting your returns with growth biotech while keeping your long-term portfolio turnover low.
Following prudent investing habits, our member's patience is rewarded.
After all, they have been holding ImmunoGen for the long term.
Moreover, our opportunistic members who added more shares prior to the binary ent for Power Catalyst Trading also enjoy huge gains.
As you can appreciate, that is far better than you start chasing after the stock that has already taken off.
Asides from ImmunoGen, you know that we had many other Biotech Binary Catalyst trades like?Madrigal Pharmaceuticals?(MDGL).
When Resmetirom posted the robust Phase 3 (MAESTRO-NASH) data, the stock flew by 359% in the ensuing days.
领英推荐
Reata Pharmaceuticals?(RETA) is another power play.
Keep in mind, this was amid the aggressive bear market of 2022 and early 2023.
As you can imagine, we also have other plays like?Seres Therapeutics?(MCRB), Avidity Biosciences (RNA), or TG Therapeutics (TGTX) that did not pop immediately.
Instead, it even dropped initially.
Here's your proof in the pudding: After Briumvi's approval, TG shares initially dropped and then rose in the following months.?
Full transparency, I made the initial correct call on TG but reverted my forecast the day before the decision after a member shared with me the data that I missed.
Immediately after realizing that I was wrong (that I should have trusted my initial intuition), I reverted back to my original recommendation for members to enjoy the huge upside as shown.?
If you missed out on these plays, no worries. I got you covered.
We're evaluating over 20 binary events stocks as well as updating our M7 long-term holdings inside IBI due to earning seasons.
You definitely don't want to miss out on those plays.
You definitely don't want to miss out on these Powerful Binary Catalyst Trades before they fly.
See what our members are saying lately ... There's?much more here?since 2017.
As such, we're offering you our?no-obligation 2-week FREE trial?to begin your biotech winning process.
And, I'm teeing up our 6th Webinar this Sunday (May 7th) with another upcoming play.
While you can certainly do it on your own, but your success rate would be much better: if you can leverage the aggregate wisdom of a powerful forecasting community with experts to your biotech gains.
High-quality market intelligence and forecasting make a huge difference between banking profits during a bear market or suffering losses.
To your success,
Harvey Tran, MD
Analyst's Disclosure:?I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours.
As a medical doctor/market expert, I'm not a registered investment advisor. Despite that I strive to provide the most accurate information, I neither guarantee the accuracy nor timeliness. Past performance does NOT guarantee future results. I reserve the right to make any investment decision for myself and my affiliates pertaining to any security without notification except where it is required by law. I'm also NOT responsible for the action of my affiliates. The thesis that I presented may change anytime due to the changing nature of information itself. Investing in stocks and options can result in a loss of capital. The information presented should NOT be construed as recommendations to buy or sell any form of security. My articles are best utilized as educational and informational materials to assist investors in your own due diligence process. That said, you are expected to perform your own due diligence and take responsibility for your action. You should also consult with your own financial advisor for specific guidance, as financial circumstances are individualized. That aside, I'm not giving you professional medical advice. Before embarking on any health-changing behavior, make sure you consult with your own doctor.
Seeking Alpha's Disclosure:?Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.